[16] While some participants in clinical studies have reported menstrual changes, these are generally attributed to the metabolic effects of weight loss rather than direct drug action on reproductive tissues, and are not classified as common adverse effects in the UK product information for GLP-1 medications
Until there are further clinical trials and professional organizations like the American Diabetes Association endorse the practice of microdosing, I would be reluctant to recommend it. If youre determined, please dont just DIY your jabs at home
These findings are very robust and compelling, says Jorge Moreno, MD, assistant professor and obesity medicine doctor at Yale Medicine in New Haven, Connecticut, who was not involved in the study
For retatrutide specifically, Phase 3 trial data are still being collected and analysed
Diabetes, Obesity, and Metabolism, 25 (4), 975-984
Glucagon: The Key to Increased Energy Expenditure Glucagon is often misunderstood as a hormone that only raises blood sugar